Metagenomi Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
Metagenomi Therapeutics, Inc. (MGX) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $0 as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2026-03-05
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
- 2025-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
- 2025-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $1.29M.
- 2024-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $1.29M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-03-31 | $1.29M 10-Q · filed 2025-08-12 |
| 2024-12-31 | $1.29M 10-K · filed 2026-03-05 |
| 2024-09-30 | $8.42M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $8.52M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $8.52M 10-Q · filed 2025-08-12 |
| 2023-12-31 | $8.52M 10-K · filed 2026-03-05 |
| 2023-09-30 | $8.52M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $8.52M 10-Q · filed 2024-11-13 |
| 2023-03-31 | $5.65M 10-Q · filed 2024-08-14 |
| 2022-12-31 | $5.65M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |